Dolutegravir plus lamivudine dual therapy - A new option for initial antiretroviral therapy

Research output: Contribution to journalArticle

Abstract

The current standard of care for treating HIV infection is the use of three antiretroviral drugs: a combination of two nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and a third agent from either the integrase strand transfer inhibitor (INSTI), boosted protease inhibitor (PI) or non-nucleoside reverse transcriptase inhibitor (NNRTI) classes. In an effort to minimize the long-term adverse effects and cost of antiretroviral therapy, the use of regimens with fewer drugs in the combination has been under active investigation. To this end, the combination of dolutegravir (DTG) plus lamivudine (3TC), two antiretroviral drugs with a long track record of efficacy and safety in the treatment of HIV infection, is undergoing clinical evaluation in treatment-naive HIV-infected participants. The promising results of the PADDLE study, with 90% of study participants achieving the primary endpoint of HIV-1 RNA < 50 copies/mL, were confirmed by the results of ACTG A5353, a phase II, single-arm, open-label study. Subsequently, GEMINI-1 and -2, two phase III, double-blind, noninferiority studies, compared DTG + 3TC to a three-drug regimen of DTG, tenofovir disoproxil fumarate and emtricitabine in 1,433 antiretroviral treatment-naive adults, and demonstrated noninferior efficacy at 48 weeks with no emergence of NRTI or INSTI mutations and a more favorable safety profile. This dual regimen should be avoided in those patients with existing mutations and chronic hepatitis B virus infection. In addition, data in patients with CD4 counts less than 200/mm3 is limited.

Original languageEnglish (US)
Pages (from-to)297-304
Number of pages8
JournalDrugs of Today
Volume55
Issue number5
DOIs
StatePublished - May 1 2019

Fingerprint

Lamivudine
Reverse Transcriptase Inhibitors
Integrases
Tenofovir
Drug Combinations
HIV Infections
Nucleotides
Safety
Mutation
Chronic Hepatitis B
Virus Diseases
Therapeutics
Standard of Care
CD4 Lymphocyte Count
Protease Inhibitors
Nucleosides
Double-Blind Method
Hepatitis B virus
Pharmaceutical Preparations
HIV-1

Keywords

  • Anti-HIV agents
  • Antiretroviral therapy
  • Dolutegravir
  • Dual therapy
  • Lamivudine

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Dolutegravir plus lamivudine dual therapy - A new option for initial antiretroviral therapy. / Fida, M.; Rizza, Stacey; Temesgen, Zelalem.

In: Drugs of Today, Vol. 55, No. 5, 01.05.2019, p. 297-304.

Research output: Contribution to journalArticle

@article{34b7e6d934ae46dc865ca387eee555c3,
title = "Dolutegravir plus lamivudine dual therapy - A new option for initial antiretroviral therapy",
abstract = "The current standard of care for treating HIV infection is the use of three antiretroviral drugs: a combination of two nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and a third agent from either the integrase strand transfer inhibitor (INSTI), boosted protease inhibitor (PI) or non-nucleoside reverse transcriptase inhibitor (NNRTI) classes. In an effort to minimize the long-term adverse effects and cost of antiretroviral therapy, the use of regimens with fewer drugs in the combination has been under active investigation. To this end, the combination of dolutegravir (DTG) plus lamivudine (3TC), two antiretroviral drugs with a long track record of efficacy and safety in the treatment of HIV infection, is undergoing clinical evaluation in treatment-naive HIV-infected participants. The promising results of the PADDLE study, with 90{\%} of study participants achieving the primary endpoint of HIV-1 RNA < 50 copies/mL, were confirmed by the results of ACTG A5353, a phase II, single-arm, open-label study. Subsequently, GEMINI-1 and -2, two phase III, double-blind, noninferiority studies, compared DTG + 3TC to a three-drug regimen of DTG, tenofovir disoproxil fumarate and emtricitabine in 1,433 antiretroviral treatment-naive adults, and demonstrated noninferior efficacy at 48 weeks with no emergence of NRTI or INSTI mutations and a more favorable safety profile. This dual regimen should be avoided in those patients with existing mutations and chronic hepatitis B virus infection. In addition, data in patients with CD4 counts less than 200/mm3 is limited.",
keywords = "Anti-HIV agents, Antiretroviral therapy, Dolutegravir, Dual therapy, Lamivudine",
author = "M. Fida and Stacey Rizza and Zelalem Temesgen",
year = "2019",
month = "5",
day = "1",
doi = "10.1358/dot.2019.55.5.2962947",
language = "English (US)",
volume = "55",
pages = "297--304",
journal = "Drugs of Today",
issn = "1699-3993",
publisher = "Prous Science",
number = "5",

}

TY - JOUR

T1 - Dolutegravir plus lamivudine dual therapy - A new option for initial antiretroviral therapy

AU - Fida, M.

AU - Rizza, Stacey

AU - Temesgen, Zelalem

PY - 2019/5/1

Y1 - 2019/5/1

N2 - The current standard of care for treating HIV infection is the use of three antiretroviral drugs: a combination of two nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and a third agent from either the integrase strand transfer inhibitor (INSTI), boosted protease inhibitor (PI) or non-nucleoside reverse transcriptase inhibitor (NNRTI) classes. In an effort to minimize the long-term adverse effects and cost of antiretroviral therapy, the use of regimens with fewer drugs in the combination has been under active investigation. To this end, the combination of dolutegravir (DTG) plus lamivudine (3TC), two antiretroviral drugs with a long track record of efficacy and safety in the treatment of HIV infection, is undergoing clinical evaluation in treatment-naive HIV-infected participants. The promising results of the PADDLE study, with 90% of study participants achieving the primary endpoint of HIV-1 RNA < 50 copies/mL, were confirmed by the results of ACTG A5353, a phase II, single-arm, open-label study. Subsequently, GEMINI-1 and -2, two phase III, double-blind, noninferiority studies, compared DTG + 3TC to a three-drug regimen of DTG, tenofovir disoproxil fumarate and emtricitabine in 1,433 antiretroviral treatment-naive adults, and demonstrated noninferior efficacy at 48 weeks with no emergence of NRTI or INSTI mutations and a more favorable safety profile. This dual regimen should be avoided in those patients with existing mutations and chronic hepatitis B virus infection. In addition, data in patients with CD4 counts less than 200/mm3 is limited.

AB - The current standard of care for treating HIV infection is the use of three antiretroviral drugs: a combination of two nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and a third agent from either the integrase strand transfer inhibitor (INSTI), boosted protease inhibitor (PI) or non-nucleoside reverse transcriptase inhibitor (NNRTI) classes. In an effort to minimize the long-term adverse effects and cost of antiretroviral therapy, the use of regimens with fewer drugs in the combination has been under active investigation. To this end, the combination of dolutegravir (DTG) plus lamivudine (3TC), two antiretroviral drugs with a long track record of efficacy and safety in the treatment of HIV infection, is undergoing clinical evaluation in treatment-naive HIV-infected participants. The promising results of the PADDLE study, with 90% of study participants achieving the primary endpoint of HIV-1 RNA < 50 copies/mL, were confirmed by the results of ACTG A5353, a phase II, single-arm, open-label study. Subsequently, GEMINI-1 and -2, two phase III, double-blind, noninferiority studies, compared DTG + 3TC to a three-drug regimen of DTG, tenofovir disoproxil fumarate and emtricitabine in 1,433 antiretroviral treatment-naive adults, and demonstrated noninferior efficacy at 48 weeks with no emergence of NRTI or INSTI mutations and a more favorable safety profile. This dual regimen should be avoided in those patients with existing mutations and chronic hepatitis B virus infection. In addition, data in patients with CD4 counts less than 200/mm3 is limited.

KW - Anti-HIV agents

KW - Antiretroviral therapy

KW - Dolutegravir

KW - Dual therapy

KW - Lamivudine

UR - http://www.scopus.com/inward/record.url?scp=85066461106&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066461106&partnerID=8YFLogxK

U2 - 10.1358/dot.2019.55.5.2962947

DO - 10.1358/dot.2019.55.5.2962947

M3 - Article

VL - 55

SP - 297

EP - 304

JO - Drugs of Today

JF - Drugs of Today

SN - 1699-3993

IS - 5

ER -